New data on the use of enzyme replacement therapies during pregnancy and breastfeeding in Pompe disease

A Franco-Dutch study analysed the course of 14 pregnancies in 11 patients with Pompe disease who were being treated with alglucosidase alfa (Myozyme®) or avalglucosidase alfa (Nexviadyme®).

  • No adverse effects were observed in either the mother or the child during the eight pregnancies in which treatment was continued.
  • Breastfeeding whilst taking Myozyme® appears to be safe. However, the study does not provide data on breastfeeding whilst taking Nexviadyme®.
  • Adjusting the dosage in line with weight gain did not prevent the slight, temporary decline in motor and respiratory function observed during pregnancy.